US FDA declines to approve expanded use of Alnylam's heart-disease drug

Reuters
2023.10.09 11:36
Oct 9 (Reuters) - The U.S. Food and Drug Administration has declined to approve the expanded use of Alnylam Pharmaceuticals’ (ALNY.O) drug to treat a rare and fatal heart disease, citing insufficient evidence of clinical meaningfulness, the company said on Monday.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.